Lumeda Inc. is a medical technology company advancing photodynamic therapy (PDT) as an adjuvant treatment for patients with non-small cell lung cancer (NSCLC) and other thoracic malignancies. Lumeda’s breakthrough light dosimetry product called DigiLum™ is designed to activate a photosensitizer drug and deliver PDT to reduce the recurrence of cancer and enhance antitumor immunity. DigiLum™ applies advanced photonics and proprietary Artificial Intelligence (AI) software to enable thoracic surgeons to control dosimetry, reduce treatment time and capture data for future treatment planning.